Anteris Technologies Global Corp (AVR) Stock Analysis
Verdict: AVOID
Severe cash burn ($79.8M FCF/yr) against $12.6M cash creates imminent dilution risk, overriding early-stage TAVR technology potential.
Investment score: 20/100
Analysis as of
Is Anteris Technologies Global Corp stock worth reviewing? The TradeMates thesis
The model evaluates Anteris Technologies as a high-risk speculative asset due to severe cash runway exhaustion ($12.58M cash vs $79.76M annual burn) and negative total equity, despite clinical promise in its DurAVR heart valve.
7-factor investment score
- Valuation: 10/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 10/100 (weight 10%)
- Analyst Consensus: 60/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Anteris Technologies Global Corp opportunities and risks
What speaks for AVR
- DurAVR Novel Biomimetic TAVR Valve Design
What speaks against AVR
- Imminent Equity Dilution and Cash Runway Exhaustion
Peers and competitors
- IART
- PRCT
- CBLL
- SIBN
- VREX
- QDEL
- ANGO
- IMR.AX
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| AVR | n/a | 341.5x | n/a | 37.0% | -4619.7% | -11.5% |
| IART | n/a | 0.6x | 11.3x | 53.7% | -0.4% | 3.9% |
| PRCT | n/a | 2.9x | n/a | 63.7% | -32.5% | -12.9% |
| CBLL | n/a | 8.8x | n/a | 88.9% | -64.7% | -6.3% |
| SIBN | n/a | 3.8x | n/a | 79.5% | -6.9% | -0.5% |
| VREX | 35.2x | 0.9x | 12.1x | 34.3% | 2.6% | -2.6% |
| Peer median | n/a | 2.9x | n/a | 63.7% | -6.9% | -2.6% |
Frequently asked questions about Anteris Technologies Global Corp (AVR)
Is AVR stock a good investment?
The TradeMates model rates Anteris Technologies Global Corp as AVOID with an investment score of 20/100. The model evaluates Anteris Technologies as a high-risk speculative asset due to severe cash runway exhaustion ($12.58M cash vs $79.76M annual burn) and negative total equity, despite clinical promise in its DurAVR heart valve. This is algorithmic model output, not personal investment advice.
Is AVR stock a buy?
The TradeMates model verdict for AVR is AVOID with an investment score of 20/100. Treat this as a model signal to review, not a personal buy recommendation.